What are the Mechanisms of Tumor Resistance to ADCC?
Tumors can develop resistance to ADCC through various mechanisms, including:
Downregulation or mutation of the target antigen, making it less recognizable by monoclonal antibodies. Expression of inhibitory molecules such as PD-L1 that suppress NK cell activity. Secretion of immunosuppressive cytokines that inhibit the function of effector cells.
Understanding these mechanisms is crucial for developing strategies to overcome resistance and enhance the efficacy of ADCC-based therapies.
